Merck & Co Takes Up Astex/Taiho SHP2 Program

Indicates Growing Pharma Interest

Merck & Co joins ranks of big pharma firms pursuing the SHP2 area of oncology as it picks up global rights to a portfolio of inhibitors originating from two affiliates of Japan's Otsuka Pharmaceutical.

Cancer Research
• Source: Shutterstock

Otsuka Holdings Co., Ltd. group companies Taiho Pharmaceutical Co. Ltd. and Astex Pharmaceuticals Ltd. have exclusively licensed to Merck & Co., Inc. global rights to their joint small molecule drug discovery program targeting SHP2, a KRAS-related oncology target gaining increasing big pharma attention, particularly for combination use.

The US major (which operates as MSD outside North America) already held an option to the early-stage program as part of an existing oncology collaboration which the two firms signed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By 

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By 

The French drugmaker is expanding its neurology activities with the $470m deal.